Long term Follow-Up of Surgical Microdiscectomy Versus Transforaminal Epidural Steroid Injection for Sciatica Secondary to Herniated Lumbar Disc: Results from the NERVES Trial
This long-term follow-up of the NERVES trial found no statistically significant differences in patient-reported outcomes between surgical microdiscectomy and transforaminal epidural steroid injection for lumbar disc herniation, though over half of the injection group eventually required surgery, suggesting that long-term results should be interpreted within the context of evolving treatment pathways rather than initial allocation alone.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of adults, a sharp, shooting pain running down the leg is not just a nuisance but a barrier to daily life. This sensation, known as sciatica, often stems from a herniated disc in the lower back, where the soft cushion between the spinal bones bulges out and presses on a nerve. While many people recover with rest and medication, those with persistent pain face a difficult choice: undergo a surgical procedure to remove the pressing tissue or try a targeted injection of anti-inflammatory medicine near the nerve. For years, doctors have debated which path offers the best relief. A major study known as the NERVES trial previously showed that, in the short term, both options provided similar pain relief, suggesting that the less invasive injection could be a valid first step. However, medicine often demands a longer view. It remains unclear whether the initial choice of treatment matters years down the line, or if the body eventually finds its own way to healing regardless of the starting point.
Researchers at the Walton Centre in the United Kingdom decided to look back at the participants of that original trial to see how they were faring nearly seven years later. They reached out to the people who had been randomly assigned to either surgery or the steroid injection to ask about their current pain, their ability to move, and their overall quality of life. The goal was not just to compare the two groups again, but to understand the entire journey each patient took. Did those who started with the injection eventually need surgery? Did those who had surgery need further operations? The team gathered data from twenty-seven individuals who responded to their survey, representing a mix of men and women who had lived with the results of their initial treatment for an average of 7.3 years.
The findings paint a picture of two different paths that often lead to the same destination. When the researchers looked at the long-term pain levels and disability scores, they found no clear statistical difference between the group that started with surgery and the group that started with the injection. Both groups reported similar levels of back and leg pain, and their ability to perform daily tasks was comparable. This suggests that, over the long haul, the initial choice of treatment does not guarantee a permanently better outcome for everyone. However, the story changes when looking at what happened after the first treatment. Among the people who began with the injection, nearly half required no further invasive procedures at all. For the other half, the injection was not enough, and they eventually underwent surgery. Conversely, in the group that started with surgery, about one-third needed a second operation to fix a recurring issue.
These results suggest that the injection is not a dead end for everyone, but rather a successful first step for a significant portion of patients who can avoid surgery entirely. Yet, for many others, the injection serves as a temporary measure before the necessary surgery is performed. The study indicates that viewing these treatments as isolated, one-time fixes is less accurate than seeing them as parts of a staged strategy. A patient might start with the injection to see if it works; if it does, they avoid surgery. If it does not, they move on to the operation. The researchers noted that while the group starting with surgery had slightly lower pain scores on average, the difference was not large enough to be certain it was real, and the small number of people surveyed made it difficult to draw definitive conclusions about which path is superior for every individual.
Ultimately, this long-term follow-up highlights that the success of treatment for sciatica is often a story of adaptation rather than a single decisive moment. The data shows that a large number of patients who begin with a less invasive approach can avoid surgery, but a substantial number will still require it later. This does not mean one treatment is wrong or the other is right; rather, it suggests that the best approach may be to offer the injection first as a way to filter out those who do not need surgery, while preparing others for the possibility that they will need to cross that bridge eventually. The study reinforces the idea that medical decisions for back pain are rarely about finding a single perfect solution, but about navigating a pathway that evolves over time to suit the specific needs of the patient.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.